Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer

BACKGROUND: Combination of capecitabine and irinotecan (XELIRI regimen) is an active and well tolerated treatment for metastatic colorectal cancer (mCRC). The aim of this study was to evaluate the efficacy and safety of this regimen in combination with bevacizumab (BV), as first-line treatment for m...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Alfonso, P, Muñoz-Martin, A J, Alvarez-Suarez, S, Jerez-Gilarranz, Y, Riesco-Martinez, M, Khosravi, P, Martin, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990572/
https://www.ncbi.nlm.nih.gov/pubmed/20978503
http://dx.doi.org/10.1038/sj.bjc.6605907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990572/
https://www.ncbi.nlm.nih.gov/pubmed/20978503
http://dx.doi.org/10.1038/sj.bjc.6605907

Ejemplares similares